Sree N. Pattipati, MPharm, PhD
Adjunct Professor
559-369-2713
spattipati@chsu.edu
Degrees:
PhD in Neuropsychopharmacology, Faculty of Pharmaceutical Sciences, Panjab University, India
MPharm in General Pharmacology, Panjab University, India
BS in Pharmaceutical Sciences, Kakatiya University, India
Professional Specialty:
General Pharmacology, Neuropharmacology and Psychopharmacology
Most recent experience:
Director and Professor, Master of Science in Biomedical Sciences, CHSU
Chair, Pharmaceutical and Biomedical Sciences, College of Pharmacy, CHSU
Adjunct Professor, California State University, Fresno, CA
Research interests:
Cannabinoids; Affective and Neurodegenerative Disorders; Pain and inflammation; Fibrotic Disorders
Most recent publications and presentations:
Guanglin Luo, Ling Chen, Walter A Kostich, Brian Hamman, Jason Allen, Amy Easton, Clotilde Bourin, Michael Gulianello, Jonathan Lippy, Susheel Nara, Sreenivasulu Naidu Pattipati et al. Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain. Journal of Medicinal Chemistry 2022; 65 (6), 4534-4564
Guanglin Luo, Ling Chen, Walter A. Kostich, Brian Hamman, Jason Allen, Amy Easton, Clotilde Bourin, Michael Gulianello, Jonathan Lippy, Susheel Nara, Tarun Kumar Maishal, Kamalraj Thiyagarajan, Prasadrao Jalagam, Sreenivasulu Naidu Pattipati et al., Discovery of (S)-1-((2′,6-Bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry 2022; 65 (6), 4457-4480
Srikumar BN, Sreenivasulu Naidu Pattipati et al., Diminished responses to monoaminergic antidepressants but not ketamine in a mouse model for neuropsychiatric lupus. Journal of psychopharmacology 2019; 33(1): 25-36.
Marcin LR, Warrier J, Thangathirupathy S, Shi J, Karageorge GN, Pearce BC, Ng A, Park H, Kempson J, Li J, Zhang H, Mathur A, Reddy AB, Nagaraju G, Tonukunuru G, Gupta GVRKM, Kamble M, Mannori R, Cheruku S, Jogi S, Gulia J, Bastia T, Sanmathi C, Aher J, Kallem R, Srikumar BN, Vijaya kumar K, Sreenivasulu Naidu Pattipati et al., BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder. ACS Med. Chem. Lett., 2018, 9 (5), 472–477
Bristow LJ, Guli J, Weed MR, Srikumar BN, Li Y-W, Graef JD, Sreenivasulu Naidu Pattipati et al., Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4- methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-D- Aspartate 2B (GluN2B) Receptor Negative Allosteric Modulator with Potential in Treatment Resistant Depression. Journal of Pharmacology and Experimental Therapeutics 2017, 363 (3) 377-393.